Evidence map›Paper›PMID 34017927›Full record

ArticleTobacco prevention & cessation2021

Cue restricted smoking increases quit rates with varenicline.

Jaqueline R Scholz, Tania O Abe, Patricia V Gaya, Bianca Bellini, Iana R A de Moraes, Juliana R Santos, Paulo R X Tomaz, Paulo C de Lima Santos, Serena Tonstad

Open access · goldAbstract read
In one paragraph

Article in Tobacco prevention & cessation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Jaqueline R ScholzDepartment of Preventive Medicine, Heart Institute, University of Sao Paulo, Sao Paulo, Brazil.
Tania O AbeDepartment of Preventive Medicine, Heart Institute, University of Sao Paulo, Sao Paulo, Brazil.
Patricia V GayaDepartment of Preventive Medicine, Heart Institute, University of Sao Paulo, Sao Paulo, Brazil.
Bianca BelliniDepartment of Preventive Medicine, Heart Institute, University of Sao Paulo, Sao Paulo, Brazil.
Iana R A de MoraesDepartment of Preventive Medicine, Heart Institute, University of Sao Paulo, Sao Paulo, Brazil.
Juliana R SantosLaboratory of Genetics and Molecular Cardiology, Heart Institute, University of Sao Paulo, Sao Paulo, Brazil.
Paulo R X TomazLaboratory of Genetics and Molecular Cardiology, Heart Institute, University of Sao Paulo, Sao Paulo, Brazil.
Paulo C de Lima SantosDepartment of Pharmacology, Paulista School of Medicine, Federal University of Sao Paolo, Sao Paulo, Brazil.
Serena TonstadDepartment of Preventive Cardiology, Oslo University Hospital, Oslo, Norway.
Universidade de São Paulo · BROslo University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionVarenicline effectively helps smokers quit by reducing withdrawal symptoms and blocking the reward of smoking. However, most quitters return to smoking within one year. 'Cue Restricted Smoking' is a behavioral technique designed to increase quit rates by asking smokers attempting to quit to restrict smoking to the standing position, while alone, in an isolated area facing a wall, with the cigarette as the only stimulus.

methodsUsing retrospective clinic records we compared quit rates in 281 smokers (50% males) instructed in the cue restricted smoking cessation method during 2016-2018 to quit rates in 324 smokers (46% males) advised to completely stop smoking on the target quit date which we previously used during 2011-2014. All were prescribed varenicline for 12 weeks alone, with the addition of bupropion if needed after 4 weeks. Follow-up consisted of behavioral support at 4-6 visits during active drug treatment and telephone counselling at 24 and 52 weeks. The smoking cessation rate was confirmed with exhaled carbon monoxide at the clinic visit at 12 weeks and only by telephone at 52 weeks.

resultsThe mean age of smokers was 49 years in both groups and the number of cigarettes smoked daily was similar (18/day in the cue restricted vs 19/day in the target quit day group). The smoking cessation rate at 12 weeks was 75% in the cue restricted versus 45% in the target quit day group (relative risk, RR=1.8; 95% CI: 1.4-2.2, p<0.001). At 52 weeks the quit rate was 65% vs 34%, respectively (RR=1.9; 95% CI: 1.5-2.4, p<0.001).

conclusionsCue restricted smoking was associated with a substantially increased chance of quitting compared with standard advice during treatment with varenicline. These results should be further studied in a randomized controlled trial.

Indexed as

behavioral techniquenicotine dependencesmoking cessationtarget quit dayvarenicline

Identifiers

PMID34017927
PMCPMC8114580
OpenAlexW3162879750

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.